Skip to content

Replimune Group REPL Finance Lease, Principal Payments

Finance Lease, Principal Payments at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Roivant Sciences logo
Roivant SciencesROIV
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's finance lease, principal payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's finance lease, principal payments?
Replimune Group (REPL) reported finance lease, principal payments of $195K in Q4 2025.
How has Replimune Group's finance lease, principal payments changed year-over-year?
Replimune Group's finance lease, principal payments increased by 22.6% year-over-year, from $159K to $195K.
What is the long-term trend for Replimune Group's finance lease, principal payments?
Over 3 years (2022 to 2025), Replimune Group's finance lease, principal payments has grown at a 31.4% compound annual growth rate (CAGR), from $264K to $599K.